Corcept Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Corcept Therapeutics es Joseph Belanoff , nombrado en Jan 1999, tiene una permanencia de 25.83 años. compensación anual total es $9.34M, compuesta por 11.6% salario y 88.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.88% de las acciones de la empresa, por valor de $178.50M. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 23.1 años, respectivamente.
Información clave
Joseph Belanoff
Chief Executive Officer (CEO)
US$9.3m
Compensación total
| Porcentaje del salario del CEO | 11.6% |
| Permanencia del CEO | 25.8yrs |
| Participación del CEO | 2.9% |
| Permanencia media de la dirección | 4yrs |
| Promedio de permanencia en la Junta Directiva | 23.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 28% But Its P/E Still Looks Reasonable
Sep 28
If EPS Growth Is Important To You, Corcept Therapeutics (NASDAQ:CORT) Presents An Opportunity
Sep 06Investors Still Waiting For A Pull Back In Corcept Therapeutics Incorporated (NASDAQ:CORT)
Aug 01With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$140m |
| Jun 30 2024 | n/a | n/a | US$125m |
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
| Sep 30 2019 | n/a | n/a | US$87m |
| Jun 30 2019 | n/a | n/a | US$78m |
| Mar 31 2019 | n/a | n/a | US$76m |
| Dec 31 2018 | US$6m | US$680k | US$75m |
| Sep 30 2018 | n/a | n/a | US$152m |
| Jun 30 2018 | n/a | n/a | US$148m |
| Mar 31 2018 | n/a | n/a | US$142m |
| Dec 31 2017 | US$4m | US$647k | US$129m |
Compensación vs. Mercado: La compensación total ($USD9.34M) de Joseph está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD7.88M).
Compensación vs. Ingresos: La compensación de Joseph ha aumentado más de un 20% en el último año.
CEO
Joseph Belanoff (67 yo)
25.8yrs
Permanencia
US$9,337,734
Compensación
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 25.8yrs | US$9.34m | 2.88% $ 178.5m | |
| CFO & Treasurer | 3.7yrs | US$3.72m | 0.012% $ 739.5k | |
| President of Endocrinology | 8.6yrs | US$3.91m | 0.10% $ 6.2m | |
| Chief Development Officer | 3.3yrs | US$3.86m | 0.0055% $ 342.2k | |
| Chief Business Officer & Secretary | 10.8yrs | US$3.96m | 0.040% $ 2.5m | |
| Chief Accounting & Technology Officer | 4.3yrs | sin datos | 0.0095% $ 584.8k | |
| Chief Scientific Officer | 4.3yrs | US$3.11m | 0.11% $ 7.0m | |
| Chief Human Resources & Communications Officer | 3.3yrs | sin datos | sin datos | |
| President of Emerging Markets | less than a year | sin datos | sin datos | |
| President of Oncology | less than a year | sin datos | sin datos |
4.0yrs
Permanencia media
53.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de CORT se considera experimentado (4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 25.8yrs | US$9.34m | 2.88% $ 178.5m | |
| Independent Director | 25.8yrs | US$492.53k | 5.07% $ 313.6m | |
| Independent Director | 20.3yrs | US$509.03k | 1.25% $ 77.6m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman | 25.8yrs | US$1.26m | 2.11% $ 130.8m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 4.7yrs | US$511.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 5.2yrs | US$488.53k | 0% $ 0 |
23.1yrs
Permanencia media
68.5yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de CORT son experimentados ( 23.1 años antigüedad media).